Retatrutide Units Per Milligram: How Compounding Math Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• Retatrutide is investigational. It is not FDA-approved, and FormBlends does not sell or supply it. This page is educational only.
• An insulin syringe measures volume in units, not peptide mass in milligrams. The two only line up after a pharmacist chooses a specific dilution.
• The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) used pre-filled pens at concentrations Lilly set internally, not user-mixed vials.
• Forum-shared unit charts assume an unverified vial label and a sterile reconstitution process performed outside a pharmacy. Both assumptions break down quickly.
• The math itself is simple arithmetic; the regulated parts (sterility, peptide-content verification, clinician oversight) are not user-solvable.

Direct answer

There is no fixed unit-per-milligram number for retatrutide. The conversion depends on the diluent volume a pharmacy adds during reconstitution. A vial mixed at one concentration produces a different unit reading than the same vial mixed at twice the dilution. Phase 2 trial participants did not perform this math; they received pre-filled pens. The question only arises in grey-market settings where the safety architecture of clinical use has been removed.

Table of contents

1. Why this question gets asked the wrong way
2. What an insulin syringe actually measures
3. The formula clinical pharmacists use
4. Why the same milligram dose produces different unit readings
5. How the Phase 2 trial side-stepped the math entirely
6. What a 503A compounding pharmacy does differently
7. The four assumptions in every forum unit chart
8. Where small-volume syringe accuracy breaks down
9. The contrary view: why some clinicians defend patient self-calculation
10. Decision framework
11. FAQ
12. Sources

Why this question gets asked the wrong way

The phrase "how many units of retatrutide should I take" presupposes two things that are not true: that a fixed unit-per-milligram conversion exists, and that retatrutide is available for prescribed self-administration. Neither holds in May 2026.

A more accurate version of the question would be: "Given a specific vial labeled with a specific peptide mass and reconstituted in a specific volume of diluent, what syringe volume corresponds to a specific milligram dose?" That version has a clear arithmetic answer. The original phrasing does not, because it skips over the variables that determine the result.

Most of the confusion comes from comparing peptides to insulin. Insulin ships pre-diluted from the manufacturer at U-100 strength (100 units per mL of a defined potency). The syringe and the medicine were designed together. Lyophilized peptides ship dry. They have no unit equivalent until someone adds water.

What an insulin syringe actually measures

A U-100 insulin syringe is graduated in volume, not mass. The "unit" on its barrel is one one-hundredth of a milliliter. So 50 units is 0.5 mL of fluid, regardless of what dissolved peptide is in that fluid.

The "unit" label is a holdover from insulin manufacturing, where one mL of U-100 insulin contains a defined biological potency of insulin. The syringe label only happens to match the medicine because both were calibrated to the same concentration.

For any other compound, the unit reading on the syringe is a volume reading. To translate that into peptide mass you need the concentration of the solution. No concentration, no conversion.

The formula clinical pharmacists use

Pharmacy compounding uses a single equation:

concentration (mg per mL) = total peptide mass (mg) divided by diluent volume (mL)

Once concentration is known, the inverse step gives volume per dose:

dose volume (mL) = target dose (mg) divided by concentration (mg per mL)

And the syringe reading is just:

syringe units = dose volume (mL) multiplied by 100

Three multiplications and one division. The math is taught in any introductory pharmaceutical calculations course. The hard parts are the inputs, not the equation.

Why the same milligram dose produces different unit readings

Suppose a vial contains 10 mg of peptide. The unit reading for a 2 mg dose depends entirely on how much diluent was added:

Diluent added	Concentration	Volume for 2 mg	Syringe reading
1 mL	10 mg per mL	0.20 mL	20 units
2 mL	5 mg per mL	0.40 mL	40 units
2.5 mL	4 mg per mL	0.50 mL	50 units
4 mL	2.5 mg per mL	0.80 mL	80 units

Same vial, same dose, four different unit readings. The "right" answer is whichever one matches the dilution the dispensing pharmacy actually used. There is no universal chart.

Phase 2 retatrutide doses ranged from 0.5 mg weekly during titration up to 12 mg weekly at maintenance (Jastreboff et al., NEJM 2023). A pharmacy preparing those doses would choose a concentration that puts the maintenance dose in a comfortable syringe range (typically 25 to 60 units), then back-calculate the diluent volume needed.

How the Phase 2 trial side-stepped the math entirely

Trial participants did not reconstitute anything. Eli Lilly supplied retatrutide as a pre-filled pen device with the concentration set at the factory and the dose selected by a click mechanism. Participants pressed the pen against the skin and the device delivered a fixed volume of a fixed-concentration solution.

This is the same delivery model Lilly uses for tirzepatide (Mounjaro and Zepbound) and Novo Nordisk uses for semaglutide (Ozempic and Wegovy). The patient never sees milligrams or units; they see a numbered dial.

The trade-off is that the manufacturer absorbs all the variability. They control the lyophilization, the buffer, the diluent, the fill volume, the device tolerances, and the cold chain. Each pen is identical to within manufacturing tolerances. None of that infrastructure exists outside the regulated supply chain.

What a 503A compounding pharmacy does differently

A 503A compounding pharmacy fills patient-specific prescriptions under state board of pharmacy oversight. For an approved compound (not retatrutide, which is not approved and not legally compoundable for general patient use), the pharmacy receives the active ingredient from an FDA-registered bulk supplier, runs identity and potency testing under USP 797 standards, mixes a specific batch, and dispenses it labeled with concentration, beyond-use date, and per-dose volume.

The patient or caregiver receives a vial with a label like "5 mg per mL" and a syringe with the matching graduation. The pharmacy did the concentration math; the patient does not need to.

None of this applies to retatrutide today. Retatrutide is investigational. There is no FDA-approved version, so there is no lawful 503A compounded version either. The 503A framework only covers preparation of approved drugs.

The four assumptions in every forum unit chart

Online "retatrutide unit chart" posts share a similar format: a table with milligram doses on one axis, diluent volumes on the other, and unit readings in the cells. The math is correct. The problems are upstream:

Assumption 1. The vial label is accurate. Most grey-market peptide vendors are not registered with the FDA, do not test individual lots, and do not maintain chain-of-custody documents. A vial labeled "10 mg retatrutide" may contain a different mass, a different peptide, or impurities. Independent testing of grey-market GLP-1 and dual-agonist products has found peptide content ranging from zero percent to over the labeled amount, sometimes containing unrelated compounds.

Assumption 2. The peptide is identity-verified retatrutide. Mass spectrometry confirms peptide sequence. Without it, the buyer is trusting the label.

Assumption 3. Sterility is intact. Lyophilized peptides shipped without temperature control may degrade. Once reconstituted in a non-sterile environment, the product is no longer parenteral-grade.

Assumption 4. The user has clinician oversight for side effects. Phase 2 participants had biweekly labs, ECGs, and a study physician on call. Forum users do not.

The unit chart math is the last problem in this chain, not the first.

Where small-volume syringe accuracy breaks down

U-100 insulin syringes are graduated in either 1-unit or 2-unit increments depending on size. A standard 0.3 mL (30-unit) syringe has 1-unit graduations; a 1 mL (100-unit) syringe usually has 2-unit graduations.

At very small volumes the relative error grows. A misread of one unit on a 5-unit dose is 20 percent off. A misread of one unit on a 50-unit dose is 2 percent off. This is why pharmacy compounding favors concentrations that keep the typical dose in the 25 to 60 unit range and avoid sub-10-unit volumes.

The relevant point: the limit on dosing precision in self-injection is not just the math, it is the resolution of the marked lines on a 0.3 mL barrel.

The contrary view: why some clinicians defend patient self-calculation

A subset of clinicians, particularly in functional and longevity medicine, argues that informed patients can be taught to perform compounding math safely when supplies are vetted and clinician oversight is in place. The argument has several components.

First, insulin-dependent diabetics calculate doses every day. The cognitive task of converting milligrams to syringe units is well within ordinary patient capability. The educational system already exists.

Second, in the case of FDA-approved injectables, some 503A pharmacies dispense multi-dose vials that require the patient to draw their own dose. The Wegovy auto-injector model is one choice; the multi-dose vial model is another. The math is the same.

Third, the alternative (mandatory pre-filled pens) is expensive and constrains dose flexibility. For titration off-label or for microdosing protocols, pre-filled pens at fixed strengths are clumsy.

These arguments are reasonable in the abstract. They do not apply to retatrutide in May 2026 because the necessary preconditions (vetted supply, identity-verified peptide, clinician oversight, lawful prescription) are absent. The self-calculation defense presupposes the rest of the system is intact. For investigational drugs accessed outside trials, it is not.

Decision framework

If you are enrolled in a retatrutide clinical trial:

• The trial supplies the drug in a pre-filled pen. You will not encounter the math.
• All dose questions go to the trial coordinator, not online forums.

If you are considering trial enrollment:

• ClinicalTrials.gov lists active TRIUMPH-program sites. Enrollment is the only lawful path to retatrutide today.
• Discuss with a clinician whether you meet inclusion criteria.

If you are reading this because you encountered a grey-market product:

• The math is not your real problem. Identity, sterility, and oversight are.
• Approved GLP-1 and dual-agonist options exist for patients who meet criteria for obesity pharmacotherapy. Speak with a licensed provider.

If you are a clinician fielding patient questions:

• Patients asking about retatrutide units are usually being marketed to by grey-market suppliers. The question is a teaching moment about regulated vs unregulated peptide supply.
• Redirect to approved options or trial enrollment.

FAQ

How many units of retatrutide should I take? There is no single answer because the unit reading depends on how concentrated the solution is. In the Phase 2 trial, participants did not handle units at all; they used pre-filled pens.

What is the relationship between milligrams and insulin-syringe units? A U-100 syringe measures volume (1 mL = 100 units). The peptide mass in a given volume depends on the concentration set at reconstitution.

Why don't drug companies just label vials in units? Because units only mean something once the dilution is fixed. Insulin works that way because the manufacturer ships it pre-diluted. Lyophilized peptides don't.

Is there a standard concentration for retatrutide? No. There is no FDA-approved version, so no standard concentration exists.

Can I calculate units myself? The arithmetic is straightforward. The unsafe parts (unverified peptide, non-sterile mixing, no clinician oversight) are not arithmetic problems.

Why do forums share unit charts? Because grey-market vendors need a way to sell undiluted vials to non-clinical buyers. The charts package the math but assume the vial label is true.

How accurate is an insulin syringe at very small volumes? Resolution drops below 10 units. A one-unit misread on a five-unit dose is 20 percent off.

What did Phase 2 trial dosing look like? Doses titrated from 0.5 mg weekly to 4, 8, or 12 mg weekly. Pens delivered fixed volumes at concentrations Lilly set internally.

Is retatrutide FDA-approved? No. As of May 2026 it remains in Phase 3 (TRIUMPH program).

Can a compounding pharmacy mix retatrutide? Not lawfully for general patient use. 503A compounding applies to approved drugs.

What should I do if a vendor offers retatrutide for sale? Recognize that the offer is outside the regulated supply chain. Identity, purity, and sterility are not verifiable.

Related guides

• Reconstituting 10 mg Retatrutide: What Compounding Pharmacies Actually Do
• Bacteriostatic Water Amounts by Retatrutide Vial Size: What Compounding Principles Actually Say
• Mixing Retatrutide With Bacteriostatic Water: What Sterile Compounding Actually Looks Like
• Retatrutide for Weight Loss: How the Triple Agonist Works
• Retatrutide 9mg vs 12mg: Which Dose Works Better?
• 20 mg Retatrutide Vials: How Compounding Pharmacies Approach the Dilution
• Tool: dosage calculator

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). New England Journal of Medicine. 2023;389:514-526.
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide in Type 2 Diabetes. The Lancet. 2023;402:529-544.
3. U.S. Food and Drug Administration. Investigational New Drug Application Process. 2024.
4. U.S. Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding: Sterile Preparations. 2023.
5. FDA. Compounding and the FDA: Section 503A vs 503B. 2023.
6. American Society of Health-System Pharmacists. Pharmaceutical Calculations for Pharmacy Technicians. 2022.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384:989-1002.
8. Jastreboff AM et al. Tirzepatide Once Weekly for Obesity. NEJM. 2022;387:205-216.
9. ClinicalTrials.gov. TRIUMPH Program (Retatrutide Phase 3) Trial Records. Accessed May 2026.
10. BD Diabetes Care. Insulin Syringe Sizing and Graduation Guide. 2023.
11. Outsourcing Facility Section 503B Registration List. FDA Drug Compounding Resources. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians and U.S.-licensed pharmacies. We do not produce, prescribe, or distribute medications and have no role in retatrutide supply at any point.

Compounded Medication Notice. Compounded preparations are not interchangeable with FDA-approved branded products and have not been reviewed by the FDA for safety or efficacy. Retatrutide is not lawfully compoundable for general patient use because it is not an FDA-approved drug.

Results Disclaimer. Clinical trial figures cited above reflect averages from controlled studies. Individual response, side effects, and tolerability vary widely. Real-world outcomes outside trial conditions are not guaranteed.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of Eli Lilly and Company and Novo Nordisk respectively. Retatrutide is an investigational compound developed by Eli Lilly and Company. FormBlends is not affiliated with, sponsored by, or endorsed by either company.